secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2026-08-06T11:33:12+00:00
Accession:  0001628280-26-053849
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Collegium Q2 net revenue $199.9M (+6% YoY); GAAP loss $0.46; guidance cut on total revenue and EBITDA
--------------------------------------------------------------------------------

- Q2 net revenue $199.9M, up 6% YoY; GAAP net loss $15.1M ($0.46 loss per share) vs prior year net income $12.0M.
- Non-GAAP adjusted net income $75.4M ($1.92 adj EPS); Adjusted EBITDA $113.8M, up 8% YoY.
- JORNAY PM revenue $46.1M (+41% YoY); AZSTARYS revenue $12.9M (partial quarter after May 12 acquisition close).
- Full-year 2026 guidance: Product Revenues $825-855M (down from $865-895M); AZSTARYS raised to $65-75M; Adjusted EBITDA $445-470M (down from $475-500M).
- Completed acquisition of AZSTARYS from Corium Therapeutics; board appointed Michael Donovan; HQ relocation to Boston planned for Q1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000162828026053849/0001628280-26-053849-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000162828026053849/coll-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-053849

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer